Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

Canada NewsWire September 14, 2016

Resverlogix Announces Participation in Upcoming Conferences

Canada NewsWire September 12, 2016

Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy

Canada NewsWire August 29, 2016

Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy

PR Newswire August 29, 2016

Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)

PR Newswire Asia August 11, 2016

Resverlogix Files 2016 Year-End Disclosure Documents

Canada NewsWire July 27, 2016

Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs

Canada NewsWire July 21, 2016

Resverlogix Announces Corporate Update Webcast

PR Newswire June 9, 2016

Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016

Canada NewsWire June 2, 2016

Milberg LLP Announces Investigation of Board of Directors' Decision to Sell Xura, Inc. to Siris Capital Group, LLC

PR Newswire May 24, 2016

Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)

Canada NewsWire May 24, 2016

The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium

Canada NewsWire April 18, 2016

Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman

Canada NewsWire April 4, 2016

Resverlogix Announces Corporate Update Webcast

Canada NewsWire March 1, 2016

Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal

Canada NewsWire January 25, 2016

Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE

Canada NewsWire November 11, 2015

Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference

Canada NewsWire November 9, 2015

Stonegate Capital Partners Initiates Coverage on Resverlogix Corp.

Accesswire November 5, 2015

Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone

Canada NewsWire October 26, 2015

Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum

Canada NewsWire October 22, 2015